A senior principal clinical biomarker scientist at a top 10 pharma discusses how they utilize and implement digital pathology. They currently use digital pathology for manual scoring of popular markers such as PD-L1 and CD8, and are exploring the use of digital pathology to decrease variability and improve reliability of results across pathologists. This stakeholder works closely with PathAI and mentions proof-of-concept data and algorithm reproducibility as top selection criteria for new vendors. Cost, turnaround time, and data analysis were mentioned as the top pain points for using this technology today. This stakeholder also discusses key market trends, such as the potential for deep-learning based H&E image analysis and the adoption of digital pathology in the U.S. compared to other parts of the world.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.